Associated Papers
Metastatic breast cancer in primary lung cancer with compound EGFR mutations: A case report.
Yang T et al.
Oncology Letters, 2026
Diagnostic accuracy of next-generation sequencing (NGS) for identifying actionable mutations in advanced non-small cell lung cancer: Systematic Review and Meta-Analysis.
Téllez Castillo N et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026
Quantum mechanics as a tool to decipher the mutational landscape of human disease.
Zavitsanou EI et al.
Progress in Biophysics and Molecular Biology, 2026
Sortilin exhibits tumor suppressor-like activity by limiting EGFR transduction function.
Lapeyronnie E et al.
Oncogene, 2026
HHLA2 promotes immune evasion in EGFR-mutant lung cancer by inhibiting CD8+ T cell glutamine metabolism via KIR3DL3 interaction.
Wu F et al.
Cancer Letters, 2026
IsoPS-DIA: Dual Functionality of Absolute Targeted Quantification and Global Proteome Profiling.
Chan HJ et al.
Analytical Chemistry, 2026
Elucidating the role of the T790M mutation in BLU-945 selectivity for mutant EGFR: structural and energetic insights.
Tariq A et al.
Journal of Computer-aided Molecular Design, 2026
A multiplex, prime editing framework for identifying drug resistance variants at scale.
Abadie FMC et al.
Cell Genomics, 2026
Prognostic impact and treatment options for EGFR-mutant non-small cell lung cancer with concurrent EGFR amplification.
Yin LX et al.
Lung Cancer (amsterdam, Netherlands), 2026
DSG2+ Cancer Stem Cells Co-Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.
Fan G et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2026
TP53 Functional-Domain-Specific Mutations Define Distinct Clinical Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Kobayashi K
Journal of Clinical Medicine, 2026
A CRISPR/Cas9-regulated dual-ring topological allosteric probe for detection of the EGFR L858R resistance mutation in CTCs.
Wang C et al.
Analytical Methods : Advancing Methods and Applications, 2026
Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer.
Rakaee M et al.
Jama Oncology, 2026
Genomic alterations and their correlation with metabolic-related genes in lung cancer.
Gaur G et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026
Unique clinical features and transcriptomic profiling of carcinogenesis in patients with familial lung cancer in Yunnan Province, Wumeng mountains, China.
Zeng J et al.
Respiratory Research, 2026
Comparative analysis of ctDNA monitoring strategies in advanced NSCLC with MET exon 14 skipping mutations treated with ensartinib.
Zhou M et al.
Npj Precision Oncology, 2026
Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer.
Azuma K et al.
Cancer Treatment and Research Communications, 2026
Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma.
Zhang T et al.
Nature, 2026
The role of APOBEC in early-stage epidermal growth factor receptor-mutant non-small cell lung cancer.
Jung HA et al.
Lung Cancer (amsterdam, Netherlands), 2026
Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.
Saito Y et al.
Nature Medicine, 2026
Individualized management strategies for advanced non-small cell lung cancer with EGFR exon 19 deletion and L861Q compound mutations based on circulating tumor DNA monitoring: A case report.
Zhu X et al.
Oncology Letters, 2026
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Targeted Protein Degradation Strategies for Lung Cancers: Focusing on Epidermal Growth Factor Receptor.
Hou M et al.
Chemistry & Biodiversity, 2026
First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?
Abdayem P et al.
Drugs, 2026
Radiological, Radiomics, and Metastatic Patterns Associated with Targetable Oncogenic Drivers on CT-Scan of Newly Diagnosed NSCLC Patients: A Comprehensive Radiogenomics Review.
Phan L et al.
Cancers, 2026
Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function.
Lam D et al.
Cancers, 2026
Magnolol suppresses TKI-resistant EGFR-mutant lung cancer by inhibiting EGFR and AXL-cMyc.
Chen CC et al.
European Journal of Pharmacology, 2026
Circulating Tumor Cell-based Molecular Responses Stratify EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Cancer.
Lee S et al.
Cancer Research and Treatment, 2026
The Effects of Variant Allele Frequency for EGFR Mutation on Early Tumor Shrinkage and Deepness of Response to Osimertinib in Patients with Metastatic Non-Small Cell Lung Cancer: An Exploratory Analysis.
Bronte G et al.
Journal of Clinical Medicine, 2026
A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non-small cell lung cancer (NSCLC).
Du Y et al.
Science Advances, 2026
Furmonertinib in lung adenocarcinoma with EGFR exon 20 insertion mutation: A case report of positive outcome.
Wang Q et al.
Medicine, 2026
An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression.
Zhang Y et al.
Nature Communications, 2026
Integrated and Comprehensive Diagnostics: An Emerging Paradigm in Precision Oncology.
Das K et al.
Cancers, 2026
EGFR mutation spectrum and clinical correlations in Tunisian Non-Small cell lung cancer patients.
Abdelmaksoud-Dammak R et al.
Molecular Biology Reports, 2026
Endostar overcomes Osimertinib-resistance mediated EGFR-activation mutation, T790M and cis-C797S triple mutations via enhancing the binding of Osimertinib to EGFR protein.
Song Z et al.
Life Sciences, 2026
Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions.
Wong AKQ et al.
Current Oncology (toronto, Ont.), 2026
EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-γ.
Zhuang WT et al.
The Journal of Clinical Investigation, 2026
Structural Studies of Fourth-Generation EGFR Inhibitors Reveal Insights into Selective T790M and C797S Targeting.
Damghani T et al.
Acs Medicinal Chemistry Letters, 2026
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge.
Bassil CF et al.
Nature Communications, 2026
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).
Li A et al.
Nature Communications, 2026
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.
Siegel F et al.
Cancer Discovery, 2026
Lung Cancer in Never-Smokers: Risk Factors, Driver Mutations, and Therapeutic Advances.
Chen PM et al.
Diagnostics (basel, Switzerland), 2026
Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutation.
Izumi H et al.
Cancer Treatment and Research Communications, 2026
Detecting EGFR Gene Mutations on a Nanobioarray Chip.
Xu F et al.
Biomedicines, 2026
Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current Therapies.
Stewart HL et al.
Journal of Medicinal Chemistry, 2026